Hupp Sabrina, Iliev Asparouh I
Institute of Anatomy, University of Bern, Baltzerstrasse 2, 3012, Bern, Switzerland.
J Neurosci Methods. 2020 Feb 15;332:108537. doi: 10.1016/j.jneumeth.2019.108537. Epub 2019 Nov 29.
A breakthrough in the microglia and macrophages field was the identification of the macrophage colony stimulating factor-1 (CSF-1) as a pro-survival factor. Its pharmacological inhibition in animals depletes rapidly all microglia and macrophages. Microglial depletion in mixed glial cultures has always represented a challenge and none of the existing approaches delivers satisfactory results.
We applied a CSF-1R inhibitor (PLX5622) in primary mouse glial cultures, analyzing microglial dose-responses, starting at different time-points and incubating for various periods of time.
We used two treatment modalities with 10 μM PLX5622 to deplete microglia: i) immediately after brain homogenization and ii) at day in vitro 12. The application of the inhibitor immediately after cell preparation depleted microglia to 8% at 1 week, to 2% at 4 weeks and to 0.5% at 6 weeks (half-time 3.5 days). When mixed glial cultures were treated starting at day in vitro 12, microglia depletion was slower (half-time 6 days) and not complete, indicating a decreased sensitivity to CSF-1. The remaining astrocytes preserved their proliferation ability, their migration in a scratch wound assay, and their pro-inflammatory (IL-6) response towards lipopolysaccharide.
The proposed approach for microglial depletion in mixed glial cultures is more effective than other existing methods and is non-toxic to non-microglial cells.
CSF-1R inhibitors are effective tools for depleting microglia in mixed glial cultures. Longer maturation of the cultures leads to a diminished sensitivity of microglia towards CSF-1. Thus, the treatment should start as early as possible after glial culture preparation.
在小胶质细胞和巨噬细胞领域的一项突破是将巨噬细胞集落刺激因子-1(CSF-1)鉴定为一种促生存因子。在动物中对其进行药理抑制会迅速耗尽所有小胶质细胞和巨噬细胞。在混合胶质细胞培养物中耗尽小胶质细胞一直是一项挑战,现有的方法都无法产生令人满意的结果。
我们在原代小鼠胶质细胞培养物中应用了一种CSF-1R抑制剂(PLX5622),分析小胶质细胞的剂量反应,从不同时间点开始并孵育不同时间段。
我们使用两种10 μM PLX5622的处理方式来耗尽小胶质细胞:i)在脑匀浆后立即进行,ii)在体外培养第12天进行。细胞制备后立即应用抑制剂,1周时小胶质细胞减少至8%,4周时减少至2%,6周时减少至0.5%(半衰期3.5天)。当从体外培养第12天开始处理混合胶质细胞培养物时,小胶质细胞的耗尽较慢(半衰期6天)且不完全,表明对CSF-1的敏感性降低。剩余的星形胶质细胞保留了它们的增殖能力、在划痕试验中的迁移能力以及对脂多糖的促炎(IL-6)反应。
所提出的在混合胶质细胞培养物中耗尽小胶质细胞的方法比其他现有方法更有效,并且对非小胶质细胞无毒。
CSF-1R抑制剂是在混合胶质细胞培养物中耗尽小胶质细胞的有效工具。培养物成熟时间越长,小胶质细胞对CSF-1的敏感性越低。因此,治疗应在胶质细胞培养制备后尽早开始。